NEWS RELEASE 12th August 2014, Mumbai - India

Performance Highlights.

Marksans Consolidated Revenue up by 40.85%, PAT up by 35.60% in quarter I, FY 2014-15

- Consolidated Revenue grew by 40.85% to Rs 2,024.00 Mn in Q1 FY 2014-15.
- EBITDA grew by 61.76% to Rs 427.97 Mn for the quarter. EBITDA margin grew to 21.14% from 18.41% for the quarter.
- Consolidated Net Profit was Rs 254.69 Mn for the Q1 FY 2014-15.
- Post Tax profits up by 35.60% over previous year same quarter.

Business Highlights

- Europe, UK Formulation business grew at 40.00% to Rs. 1,323.00 Mn from Rs. 945 Mn during Q1 FY 2014-15.
- US & North America Formulation business grew at 67.77% to Rs. 354 Mn from Rs. 211 Mn during Q1 FY 2014-15.
- Company achieved revenue of Rs. 189 Mn from Australia & NZ Formulation business.
- Rest of World(Asia, Africa & CIS) Formulation business grew at 74.44% to Rs. 157 Mn from Rs. 90 Mn during Q1 FY 2014-15.

Revenue Figures - Consolidated

	INR in million		
	Q1 FY 2014-15	Q1 FY 2013-14	Growth %
Europe, UK - Formulations	1323	945	40.00%
US & North America - Formulations	354	211	67.77%
Australia & NZ - Formulations	189	191	-1.05%
Rest of World(ROW) - Africa, Asia & CIS	157	90	74.44%
Consolidated Revenue from operations	2024	1437	40.85%

www.marksanspharma.com

About Marksans Pharma Limited

Marksans Pharma Limited(www.marksanspharma.com) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies like USFDA, UK MKRA, Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain management, Gastroenterologicals and Anti-allergies. The company is marketing these products globally.

Marksans Pharma Limited
11, Lotus Business Park, Off New Link Road, Andheri – West, Mumbai – 400 053, India
Tel:- +91 22 4001 2000, ax:- +91 22 4001 2099